First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Table 1 Patient demographics and baseline disease characteristics

Parameter/characteristic	Lumiracoxib 400 mg once daily (n = 144)	Celecoxib 200 mg twice daily (n = 145)	Placebo (n = 75)
Age (years; mean ± SD)	64.7 ± 7.8	65.3 ± 9.5	64.8 ± 9.0
Males (n [%])	66 (45.8)	54 (37.2)	33 (44.0)
Females (n [%])	78 (54.2)	91 (62.8)	42 (56.0)
Disease duration (years; mean ± SD)	7.3 ± 6.7	7.5 ± 6.7	7.6 ± 8.6
VAS actual^a pain intensity (mm; mean ± SD)	65.8 ± 11.5	64.1 ± 11.5	64.4 ± 12.4
VAS worst^b pain intensity (mm; mean ± SD)	75.7 ± 11.5	75.5 ± 11.8	74.3 ± 11.2
VAS average^c pain intensity (mm; mean ± SD)	57.9 ± 12.5	56.9 ± 11.6	57.0 ± 14.8
WOMAC™ scores (mean ± SD)
Total	52.3 ± 12.6	53.9 ± 12.5	53.2 ± 11.6
Pain	10.6 ± 2.9	11.1 ± 2.9	10.8 ± 2.6
Stiffness	4.0 ± 1.7	4.0 ± 1.7	4.1 ± 1.3
DPDA	37.8 ± 9.2	38.8 ± 9.2	38.3 ± 8.7

^aVAS actual pain intensity = mean of 3-hour and 5-hour assessments. ^bVAS worst pain intensity = worst pain intensity in the past 12 hours. ^cVAS average pain intensity = average pain intensity in the past 12 hours. DPDA, difficulty in performing daily activities; SD, standard deviation; VAS, visual–analogue scale; WOMAC™, Western Ontario and McMaster Universities Osteoarthritis Index.

ISSN: 1478-6362